The 6.5% notes are due 2027

Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by Assertio Holdings, Inc. of $70 million aggregate principal amount of its 6.50% convertible senior notes due 2027, which included $10 million principal amount of notes pursuant to the exercise in full of the initial purchaser’s option to purchase additional notes.

Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. Assertio's commercial portfolio of branded products focuses on three areas: neurology; hospital; and pain and inflammation.

The Davis Polk corporate team included partner Yasin Keshvargar and associates Stephen H. Karp and Chase Belford. The equity derivatives team included partner Mark M. Mendez and associates Hanbing Zhang and Amy Cheng. The tax team included partner Po Sit and counsel Aliza Slansky. The intellectual property and technology transactions team included partner David R. Bauer and associates Alison T. Chin. All members of the Davis Polk team are based in the New York office.